Trends towards dimensional approaches in understanding psychiatric disorders may also be applied to addictive disorders. Advances in our understanding of the neurobiology of addiction can inform these efforts. Furthermore, dimensional approaches to addiction, such as the proposed Addictions Neuroclinical Assessment (ANA), may be used in identifying novel addiction biomarkers, and refining ones that currently exist. These biomarkers, derived from both an understanding of the neurobiology of addiction and behavioral phenotypes, represent a departure from traditional markers of alcohol-relevant biomarkers, such as tests of liver function (LFTs). We posit that a potential addiction-relevant biomarker is reinforcer pathology, found to be relevant across addictions to different substances, and which may offer a target for modification through the use of episodic future thinking.

在理解精神疾病方面朝着维度方法发展的趋势也可以应用于成瘾性疾病。我们对成瘾的神经生物学的理解的进步可以为这些努力提供信息。此外，成瘾的维度方法（例如，建议的成瘾神经临床评估（ANA））可用于识别新型成瘾生物标记，并完善目前存在的生物标记。从对成瘾的神经生物学和行为表型的理解中得出的这些生物标志物代表了与酒精相关生物标志物的传统标志物（例如肝功能测试）的背离。我们假设潜在的与成瘾有关的生物标志物是强化剂病理，发现与成瘾不同物质有关，